Project Grant HT94252410669
Award Date
8/15/24
Completion Date
8/14/27
Dollars Obligated
$2.1M
Federal Agency
Defense Health Agency
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This federal Project Grant award of $1,782,155.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Mayo Clinic to identify novel drug targets for lethal prostate cancer using liquid biopsy techniques. The award period runs from April 1, 2025 to March 31, 2028. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations...
The federal Project Grant award of $161,400.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support Mayo Clinic's research project titled "AN ATLAS OF THE TUMOR IMMUNE CIRCULOME." This award, with a performance period from June 1, 2024 to May 31, 2025, aims to advance medical knowledge and improve patient care through innovative biomedical research. The Military Medical Research and Development program funds a wide range of...
The Defense Health Agency awarded a $2,455,718 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Mayo Clinic in Rochester, Minnesota. The grant supports the "NKG7-Armed Tumor-Infiltrating Lymphocyte Therapy for Metastatic Uveal Melanoma" research project, with a performance period from September 1, 2025 to August 31, 2029. The grant funding will enable the Mayo Clinic, a renowned non-profit academic medical center, to conduct advanced...
The Defense Health Agency awarded a $1,162,900 Project Grant to the Mayo Clinic in Rochester, MN under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on July 15, 2025, is for the project "LAUNCHING THE ERA OF MELANOMA SURVIVORSHIP: DEFINING TREATMENT TARGETS IN QUALITY OF LIFE AND MENTAL HEALTH" and runs through July 14, 2028. The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $564,900.00 to Mayo Clinic to support research aimed at "EXPLOITING VIRAL TROPISM TO TARGET CANCER-ASSOCIATED FIBROBLASTS IN INTRAHEPATIC CHOLANGIOCARCINOMA". The award period runs from September 1, 2024 to August 31, 2026. Mayo Clinic, a renowned non-profit academic medical center, will leverage its expertise in cancer biology, drug development,...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,291,419.00 to Mayo Clinic Arizona to conduct a Phase 1 clinical trial using autologous, MUC1-activated T cells expanded from peripheral blood in patients with relapsed and resistant ovarian cancer. The award period runs from September 1, 2024 to August 31, 2028. This research aims to advance innovative cellular immunotherapy approaches to transform...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,000.00 to Mayo Clinic to conduct research aimed at enhancing the effectiveness of immune checkpoint blockade (ICB) immunotherapy for renal cell carcinoma (RCC). The project seeks to demonstrate that disrupting the ubiquitination or phosphorylation of the RIPK1 protein in RCC tumor cells can increase their susceptibility to killing by T cells in a TNF-dependent manner, thereby...
The Mayo Clinic received a $278,250 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from August 2021 through July 2025 to develop techniques for cytokine modulation of chimeric antigen receptor T cells to increase their safety and efficacy. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions...
The Defense Health Agency awarded a $597,543.00 Project Grant to Mayo Clinic Arizona, doing business as Mayo Clinic Hospital, a nonprofit academic medical center. The grant, which runs from October 1, 2023 to September 14, 2026, is funded under the Military Medical Research and Development program (CFDA 12.420) to support research aimed at "elucidating mechanisms of CAR-T cell immunotherapy resistance and sensitivity to improve treatment of myeloma." As a nonprofit organization with...